JSP Pharmaceutical Manufacturing (Thailand) Public Past Earnings Performance
Past criteria checks 0/6
JSP Pharmaceutical Manufacturing (Thailand) Public's earnings have been declining at an average annual rate of -44.5%, while the Pharmaceuticals industry saw earnings growing at 11.3% annually. Revenues have been growing at an average rate of 16.4% per year.
Key information
-44.5%
Earnings growth rate
-48.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 16.4% |
| Return on equity | -0.3% |
| Net Margin | -0.2% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How JSP Pharmaceutical Manufacturing (Thailand) Public makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 594 | -1 | 163 | 0 |
| 30 Sep 23 | 555 | 3 | 146 | 0 |
| 30 Jun 23 | 488 | -6 | 139 | 0 |
| 31 Mar 23 | 474 | -4 | 140 | 0 |
| 31 Dec 22 | 467 | -17 | 155 | 0 |
| 30 Sep 22 | 419 | -24 | 149 | 0 |
| 30 Jun 22 | 419 | -13 | 135 | 0 |
| 31 Mar 22 | 419 | 11 | 118 | 0 |
| 31 Dec 21 | 429 | 30 | 103 | 0 |
| 30 Sep 21 | 422 | 32 | 96 | 0 |
| 30 Jun 21 | 421 | 32 | 95 | 0 |
| 31 Mar 21 | 433 | 29 | 98 | 0 |
| 31 Dec 20 | 463 | 31 | 100 | 0 |
| 31 Mar 20 | -234 | 22 | -17 | 0 |
| 31 Dec 19 | 369 | 24 | 82 | 0 |
| 31 Dec 18 | 352 | 12 | 79 | 0 |
| 31 Dec 17 | 440 | 30 | 77 | 0 |
Quality Earnings: JSP is currently unprofitable.
Growing Profit Margin: JSP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: JSP is unprofitable, and losses have increased over the past 5 years at a rate of 44.5% per year.
Accelerating Growth: Unable to compare JSP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: JSP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6%).
Return on Equity
High ROE: JSP has a negative Return on Equity (-0.3%), as it is currently unprofitable.